Combination therapy for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 3 months.
- Your colitis is moderate to severe, with active symptoms like rectal bleeding.
- Your colitis extends at least 15 cm into your colon, not just the rectum.
- You have tried one or two biologic treatments (like TNF blockers) and they didn't work or you couldn't tolerate them.
- You haven't had recent surgery to remove your colon, and you don't have certain other bowel diseases.
- You don't have active infections (like tuberculosis, hepatitis, or C. diff) and you're not on certain medications that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study compares taking tofacitinib alone versus combining it with mesalamine to keep ulcerative colitis under control. If you are currently in remission, this trial may help find the best way to prevent flare-ups.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study tests whether adding a herbal supplement called CurQD to the standard treatment vedolizumab can help control ulcerative colitis symptoms better than vedolizumab alone. It aims to see if the combination reduces inflammation and improves quality of life for people with active disease.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.